Providing a safer therapy for the crossover treatment group of Crohn's disease, psoriasis, rheumatoid arthritis, and ulcerative colitis. Some highlights:

-The treatment is a Medical Food, allowing it to avoid the drug approval process
-Proprietary patent-pending phytochemical formulation
-Important safety benefits over current drugs
-Large markets in dire need of safer, cheaper treatments
-Revenues exceeding $1 billion annually with small share